Drug Patents owned by Impax Labs Inc
1. Drug name - RYTARY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377474 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US8454998 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US8557283 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9901640 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9533046 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9463246 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9089607 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9089608 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Treatment: Treatment of parkinson's disease; treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of post-encephalitic parkinsonism; treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of parkinson's disease; treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; method of providing a therapeutically effective and stable median blood plasma level of levodopa
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 23.75MG;95MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 36.25MG;145MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 48.75MG;195MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 61.25MG;245MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.